SARS-CoV-2 presence in the cerebrospinal fluid of COVID-19 patients with acute respiratory failure: a pilot study.

Withdrawn

• Conditions: coronavirus; COVID-19; 10047438; 10007951

• Registration Number: NL-OMON49509
• Lead Sponsor: Zuyderland Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- At least 18 years of age
- Requires mechanical ventilation
- Proven SARS-CoV-2 infection
- Lumbar puncture possible within 48 hours of ICU admission
- Informed consent provided by either patient or legal representative

Exclusion Criteria

- Any contraindication for lumbar puncture
- Proven or suspected cerebrospinal fluid leak or other blood-brain barrier
defects
- Any condition known to alter cerebrospinal fluid biochemistry
- Known or suspected cause for respiratory failure, other than COVID-19
- Any disease known for decreasing pulmonary capacity or compliance

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>SARS-CoV-2 RT-PCR of cerebrospinal fluid (positive/negative)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Clinical characteristics<br /><br>- 8-week mortality<br /><br>Biochemistry and cell count of the cerebrospinal fluid<br /><br>- Leukocyte count of the cerebrospinal fluid, including differential count<br /><br>Biochemistry and cell count of serum<br /><br>- Leukocyte count<br /><br>- C-reactive protein (CRP)<br /><br>- Lactate dehydrogenase (LDH)<br /><br>- D-Dimer</p><br>